Hospital Length of Stay for Patients with Severe COVID-19: Implications for Remdesivir’s Value

Michaela R. Anderson1 · Peter B. Bach2 · Matthew R. Baldwin1

Accepted: 19 November 2020 / Published online: 14 December 2020 © The Author(s) 2020

1 Introduction

In June 2020, the Gilead Sciences chief executive officer announced that US hospitals would be charged $US3120 for a course of remdesivir for the treatment of coronavirus 2019 (COVID-19), a price roughly 33% higher than that the company plans to charge other high-income countries [1]. The sole justification offered was that remdesivir would save hospitals $US12,000 per patient by shortening hospital length of stay (LOS) by 4 days. This presumed benefit was extrapolated from the ACTT-1 trial, which found median time to recovery (an approximation of median time to hospital discharge) of 11 days in patients receiving remdesivir versus 15 days in those receiving placebo [2].

However, to be used as justification for such a high price, it is critical that the ACTT-1 finding is robust. It may not be, either because patients who were expected to be discharged within 72 h were excluded from the trial or because the outcomes of the study population are not generalizable. A subsequent open-label, adaptive, randomized trial failed to demonstrate a significant reduction in hospital LOS with remdesivir treatment [3]. Remdesivir is a 5-day treatment and can only be administered during an inpatient stay. Hospital stays that would otherwise be 5–8 days could be shortened with remdesivir therapy, but by fewer than 4 days. Patients who would otherwise be discharged in fewer than 5 days could not experience any reduction in LOS and might instead have their hospital stay prolonged to complete their treatment course. An open-label randomized trial of remdesivir demonstrated a peak in discharge rates upon completion of therapy, suggesting that physicians actually delayed discharge to complete treatment [4]. Remdesivir’s US FDA approval does not limit its use based on LOS and specifies that intravenous remdesivir be given in an in-patient setting [5, 6]. We assessed what percentage of patients with severe COVID-19 belonged to each of these LOS groups in a real-world cohort prior to the FDA’s emergency use authorization of remdesivir.

2 Methods

Our study cohort consisted of adults aged ≥18 years with severe COVID-19 consecutively hospitalized from the emergency department (ED) at New York-Presbyterian Columbia University Irving Medical Center and the Allen community hospital between March 9 and April 23, 2020, with follow-up through June 10, 2020. Data abstraction methods have been published previously [7, 8]. We defined severe COVID-19 based on remdesivir trial and FDA criteria: an initial oxygen saturation ≤94% on room air or the use of any supplemental oxygen within 24 h of ED presentation [2, 9]. LOS was measured from presentation to death or hospital discharge.

3 Results

In total, 1643 adults were admitted with severe COVID-19, after excluding 21 (1%) who were discharged in <9 days to another hospital. The median age was 67 years (interquartile range 56–78), a majority were Hispanic or Black and had one or more comorbidity, 12% required mechanical ventilation within 24 h, median LOS was 7 (3–14) days, and in-hospital 28-day mortality was 26%. In total, 586 patients
(36%) had a LOS of 1–4 days, 384 (23%) had a LOS of 5–8 days, and 673 (41%) were hospitalized for ≥9 days (Table 1). The distribution was similar when patients who died during their hospital stay were excluded (Table 1). The majority of those with a LOS of 1–4 or 5–8 days were aged ≥ 60 years (67% and 70%, respectively; Fig. 1).

### Table 1 Baseline characteristics by hospital length of stay

| Characteristics                  | Length of stay | p value |
|----------------------------------|----------------|---------|
|                                  | 1–4 days (n = 586) | 5–8 days (n = 384) | ≥9 days (n = 673) |
| Age, years                       | 68 (55–80)      | 68 (57–79)      | 67 (56–75)      | 0.03 |
| Sex, male                        | 325 (55)        | 212 (55)        | 424 (63)        | 0.008 |
| Race/ethnicity                   |                |                | 0.67 |
| White non-hispanic               | 44 (8)          | 33 (9)          | 63 (9)          | |
| Black non-hispanic               | 60 (10)         | 41 (11)         | 78 (12)         | |
| Hispanic                         | 318 (54)        | 198 (52)        | 329 (49)        | |
| Other                            | 83 (14)         | 65 (17)         | 104 (15)        | |
| Declined                         | 81 (14)         | 47 (12)         | 99 (15)         | |
| Comorbidities                    |                |                |                 |
| Asthma/COPD                       | 84 (14)         | 70 (18)         | 125 (19)        | 0.10 |
| Hypertension                     | 297 (51)        | 194 (51)        | 339 (50)        | 0.99 |
| Chronic kidney disease           | 79 (13)         | 79 (21)         | 123 (18)        | 0.009 |
| Cancer                           | 53 (9)          | 42 (11)         | 102 (15)        | 0.003 |
| Smoking                          | 42 (17)         | 52 (14)         | 83 (12)         | 0.002 |
| Diabetes                         | 209 (36)        | 153 (42)        | 280 (42)        | 0.045 |
| Pulmonary heart disease          | 33 (6)          | 24 (6)          | 45 (7)          | 0.74 |
| Comorbidities                    | 1 (0–2)         | 1 (0–3)         | 1 (0–3)         | 0.005 |
| Participation in remdesivir triala | 7 (1)          | 3 (1)           | 35 (5)          | <0.001 |
| Discharge disposition            |                |                | <0.001 |
| Home                             | 356 (61)        | 238 (62)        | 219 (33)        | |
| Rehabilitation center            | 35 (6)          | 47 (12)         | 190 (28)        | |
| Death                            | 168 (29)        | 81 (21)         | 173 (26)        | |
| Hospice                          | 27 (5)          | 18 (5)          | 30 (4)          | |
| Transferred to other hospital    | 0 (0)           | 0 (0)           | 8 (1)           | |
| Hospitalized at study completion | 0 (0)           | 0 (0)           | 53 (8)          | |

Values are presented as n (%) or median (interquartile range). P values were calculated using the Kruskal–Wallis or Chi-squared tests.

COPD chronic obstructive pulmonary disease

aGilead GS-US-540-5774 or GS-US-540-5773

4 Discussion

In our cohort, the median LOS was markedly shorter than the equivalent endpoint in the ACTT-1 trial (7 vs. 15 days). This difference raises immediate questions as to whether remdesivir could reduce LOS by the 4 days used to justify the treatment’s price. We found that only 41% of patients could both receive a 5-day course of remdesivir and have LOS shortened by 4 days or more, whereas 36% could have their LOS potentially prolonged to complete therapy.

Our evaluation is relevant to the extent that our older-adult multimorbidity-predominant cohort is representative of those with severe COVID-19; LOS may be even shorter in younger and healthier populations. Our data are from patients hospitalized before dexamethasone became standard of care. Some patients may be prescribed 10 rather than 5 days of remdesivir, which could further prolong LOS (both durations are authorized by the FDA). Whether physicians will keep patients who otherwise could be discharged to complete treatment could not be determined, but evidence suggests this will occur [4].

Re-evaluating remdesivir’s pricing, studying shorter remdesivir treatment courses, developing intranasal remdesivir [10], and implementing programs to facilitate outpatient intravenous remdesivir administration should be considered.
**Declarations**

**Funding** This study was supported in part by the National Institutes of Health (Grant numbers UL1 TR001873 to MRB and K23 HL 150280 to MRA) and the Parker B Francis Foundation. None of the listed funding sources were involved in the design or conduct of this study; the preparation, review, or approval of this manuscript; or the decision to submit this manuscript for publication.

**Conflict of interest** Dr. Anderson has no conflicts of interest that are directly relevant to the content of this article. Dr. Baldwin served as site co-investigator for Gilead Sciences Remdesivir trials GS-US-540-5774 and GS-US-540-5773 and received no funding. Dr. Bach has received personal fees and non-financial support from the American Society for Health-System Pharmacists, United Rheumatology, Oppenheimer & Co, Kaiser Permanente Institute for Health Policy, the Congressional Budget Office, America’s Health Insurance Plans, and Geisinger; personal fees from WebMD, Defined Health, JMP Securities, Mercer, Foundation Medicine, Grail, Morgan Stanley, NYS Rheumatology Society, Cello Health, Anthem, Magellan Health, EQRx, Meyer Cancer Center of Weill Cornell Medicine, and the National Pharmaceutical Council; personal fees, non-financial support, and other support from Oncology Analytics; and grants from Kaiser Permanente and Arnold Ventures. All listed support was outside the submitted work.

**Data availability** Data sharing would be considered with appropriate institutional review board approval.

**Ethics approval** Columbia University IRB#AAAS9982.

**Consent** Not applicable.

**Code availability** Code is available upon reasonable request.

**Author contributions** MRA and MRB had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design, drafting of the manuscript, and critical revision of the manuscript for important intellectual content: MRA, PB, MRB. Acquisition, analysis, and interpretation of data and statistical analysis: MRA, MRB.

**Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

**References**

1. O’Day D. An open letter from Daniel O’Day, chairman and CEO, Gilead sciences. Forst City: Business Wire; 2020.
2. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19—preliminary report. N Engl J Med. 2020;383(10):992–4.
3. Pan H, Peto R, Karim QA, et al. Repurposed antiviral drugs for COVID-19—Interim WHO SOLIDARITY trial results. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2023184.
4. Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324(11):1048–57.
5. Coronavirus (COVID-19) Update: FDA issues emergency use authorization for potential COVID-19 treatment. 2020. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment. Accessed 17 Sep 2020.
6. FDA Approves First Treatment for COVID-19. 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19. Accessed 17 Sept 2020.
7. Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;382(25):2411–8.
8. Anderson MR, Geleris J, Anderson DR, et al. Body mass index and risk for intubation or death in SARS-CoV-2 infection: a retrospective cohort study. Ann Intern Med. 2020;173:782–90.
9. Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020;383(19):1827–37.
10. Gilead Sciences. Study in participants with early stage coronavirus disease 2019 (COVID-19) to evaluate the safety, efficacy, and pharmacokinetics of remdesivir administered by inhalation. [webpage]. 2020; https://clinicaltrials.gov/ct2/show/NCT04539262?term=remdesivir&draw=3&rank=11. Accessed 17 Sept 2020.